Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
Name | Price | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-SMC1B antibody (110-190 aa) (STJ192510) | Login | Anti-SMC1B antibody (110-190 aa) (STJ192510) | ||||||||||||||||
|
||||||||||||||||||
Anti-CNMD antibody (150-230 aa) (STJ192522) | Login | Anti-CNMD antibody (150-230 aa) (STJ192522) | ||||||||||||||||
|
||||||||||||||||||
Anti-YIPF3 antibody (N-Term) (STJ192526) | Login | Anti-YIPF3 antibody (N-Term) (STJ192526) | ||||||||||||||||
|
||||||||||||||||||
Anti-FXYD5 antibody (Internal) (STJ192528) | Login | Anti-FXYD5 antibody (Internal) (STJ192528) | ||||||||||||||||
|
||||||||||||||||||
Anti-AGTR2 antibody (30-110 aa) (STJ192611) | Login | Anti-AGTR2 antibody (30-110 aa) (STJ192611) | ||||||||||||||||
|
||||||||||||||||||
Anti-CALCRL antibody (40-120 aa) (STJ192614) | Login | Anti-CALCRL antibody (40-120 aa) (STJ192614) | ||||||||||||||||
|
||||||||||||||||||
Anti-KIR2DS2 antibody (131-180 aa) (STJ192537) | Login | Anti-KIR2DS2 antibody (131-180 aa) (STJ192537) | ||||||||||||||||
|
||||||||||||||||||
Anti-CRIPTO antibody (21-70 aa) (STJ192538) | Login | Anti-CRIPTO antibody (21-70 aa) (STJ192538) | ||||||||||||||||
|
||||||||||||||||||
Anti-FPR2 antibody (130-210 aa) (STJ192622) | Login | Anti-FPR2 antibody (130-210 aa) (STJ192622) | ||||||||||||||||
|
||||||||||||||||||
Anti-GNAS antibody (171-220 aa) (STJ192545) | Login | Anti-GNAS antibody (171-220 aa) (STJ192545) | ||||||||||||||||
|
||||||||||||||||||
Anti-PIP antibody (11-60 aa) (STJ192547) | Login | Anti-PIP antibody (11-60 aa) (STJ192547) | ||||||||||||||||
|
||||||||||||||||||
Anti-CALCA antibody (71-120 aa) (STJ192548) | Login | Anti-CALCA antibody (71-120 aa) (STJ192548) | ||||||||||||||||
|
||||||||||||||||||
Anti-PZP antibody (1301-1350 aa) (STJ192551) | Login | Anti-PZP antibody (1301-1350 aa) (STJ192551) | ||||||||||||||||
|
||||||||||||||||||
Anti-SALL4 antibody (891-940 aa) (STJ192552) | Login | Anti-SALL4 antibody (891-940 aa) (STJ192552) | ||||||||||||||||
|
||||||||||||||||||
Anti-TARDBP antibody (41-90 aa) (STJ192553) | Login | Anti-TARDBP antibody (41-90 aa) (STJ192553) | ||||||||||||||||
|
||||||||||||||||||
Anti-ID3 antibody (68-117 aa) (STJ192556) | Login | Anti-ID3 antibody (68-117 aa) (STJ192556) | ||||||||||||||||
|
||||||||||||||||||
Anti-TRIP6 antibody (221-270 aa) (STJ192559) | Login | Anti-TRIP6 antibody (221-270 aa) (STJ192559) | ||||||||||||||||
|
||||||||||||||||||
Anti-TGFBRAP1 antibody (671-720 aa) (STJ192560) | Login | Anti-TGFBRAP1 antibody (671-720 aa) (STJ192560) | ||||||||||||||||
|
||||||||||||||||||
Anti-ID2 antibody (21-70 aa) (STJ192561) | Login | Anti-ID2 antibody (21-70 aa) (STJ192561) | ||||||||||||||||
|
||||||||||||||||||
Anti-FLVCR1 antibody (481-530 aa) (STJ192562) | Login | Anti-FLVCR1 antibody (481-530 aa) (STJ192562) | ||||||||||||||||
|
||||||||||||||||||
Anti-FKTN antibody (111-160 aa) (STJ192563) | Login | Anti-FKTN antibody (111-160 aa) (STJ192563) | ||||||||||||||||
|
||||||||||||||||||
Anti-PARP9 antibody (450-530 aa) (STJ192432) | Login | Anti-PARP9 antibody (450-530 aa) (STJ192432) | ||||||||||||||||
|
||||||||||||||||||
Anti-SORT1 antibody (260-340 aa) (STJ192435) | Login | Anti-SORT1 antibody (260-340 aa) (STJ192435) | ||||||||||||||||
|
||||||||||||||||||
Anti-FLRT2 antibody (170-250 aa) (STJ192439) | Login | Anti-FLRT2 antibody (170-250 aa) (STJ192439) | ||||||||||||||||
|
||||||||||||||||||
Anti-HLA-DRA antibody (100-180 aa) (STJ192452) | Login | Anti-HLA-DRA antibody (100-180 aa) (STJ192452) | ||||||||||||||||
|